AVR may get a boost from new distribitor news. Wednesday June 9, 8:30 am ET
Switzerland's Morwell Diagnostics Selects Avitar's ORALscreen(TM) On-site Drugs-of-Abuse Test For Distribution
CANTON, Mass., June 9 /PRNewswire-FirstCall/-- Avitar, Inc. (Amex: AVR - News) announced today that it is adding Morwell Diagnostics GmbH of Switzerland to its growing list of international distribution partners, now spanning Australia, Canada, Croatia, Hungary, Malaysia, Mexico, and Thailand.
"As a result of our strong experience in drugs-of-abuse testing, we know that technical product quality, reliability and support are critical selection criteria in our search for an oral-based on-site screen for drugs-of-abuse," explained Dr. E. Moradian, Managing Director of Morwell Diagnostics, GmbH. "We also highly value the continuing advancement of technology and product range. Our extensive research led us to select Avitar and the ORALscreen(TM) instant oral-based drug test, and we believe the decision will help our organization maintain a leadership position."
Dr. Moridian further noted, "The benefits of on-site drug testing are understood in Switzerland. For example, in the justice system, on-site oral testing allows drug screening to be done in the presence of individuals without the added costs of external laboratories, or the inherent risk of adulteration common with unsupervised urine collections. In schools, oral testing is a superior alternative to observed urine collection. Oral tests preserve the student's dignity, and maintain appropriate student- administration relationships."
"We are very pleased to have a market leader of Morwell Diagnostics' caliber represent Avitar. Their reputation for quality and service is well known throughout Switzerland, represent Avitar solutions," noted Pete Phildius, President & CEO of Avitar. "Our relationship with Morwell further demonstrates that Avitar's oral on-site drugs-of-abuse products are gaining acceptance on a world wide basis."
Morwell Diagnostics offers a wide range of laboratory services including lab-based urine testing. Although urine testing is well established in Switzerland, saliva testing is gaining ground, especially in non-medical settings where collection of urine is either not possible, difficult, or in settings where urine samples may be easily adulterated. A simple saliva sample collected in the presence of an officer or test administrator is preferable in these cases. The benefits of oral testing, increased hygiene and the avoidance of uncomfortable situations related to sample collection with a person in attendance, present Morwell Diagnostics with an excellent complement to the company's existing drugs-of-abuse testing products and services.
ABOUT AVITAR
Avitar, Inc. develops, manufactures and markets innovative and proprietary products in the oral fluid diagnostic market and customized polyurethane applications used in the wound dressing industry. Oral fluid diagnostics includes the estimated $1.5 billion drugs-of-abuse testing market, which encompasses the corporate workplace and criminal justice markets. Avitar's products include ORALscreen(TM), the world's first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse. Additionally, Avitar manufactures and markets HYDRASORB(TM), an absorbent topical dressing for moderate to heavy exudating wounds. For more information, see Avitar's website at http://www.avitarinc.com.
ABOUT Morwell Diagnostics GmbH
Morwell Diagnostics is a leading supplier of medical diagnostic and research reagents in Switzerland. Located just outside Z/rich and a short distance from the airport, Morwell's modern facilities are fully equipped to deliver quality products to multiple market sectors. The facilities include extensive cool rooms, quality control and technical support laboratories, a manufacturing facility for immunological products, as well as technically advanced sales and marketing offices.
Safe Harbor Statement. This release contains forward looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company's filings with the Securities and Exchange Commission. In view of such risks and uncertainties, the Company's actual results could differ materially from those anticipated in such forward looking statements.
Contact:
Peter N. Cholakis
Vice President, Marketing
(781) 821-2440 x117
pcholakis@avitarinc.com
www.avitarinc.com
--------------------------------------------------------------------------------
Source: Avitar, Inc.
News 
Market Data 
Discover 
AI
